Investigating new treatments for Ewing sarcoma using modified mithramycin
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma
This study is working on new medicines to help treat Ewing sarcoma, a type of cancer that mostly affects kids and young adults, by creating safer and more effective options than what we have now.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10846676 on NIH RePORTER |
What this research studies
This research focuses on developing new analogues of mithramycin to target the EWS-FLI1 transcription factor, which drives Ewing sarcoma, a type of cancer primarily affecting children and young adults. The study aims to create compounds that are less toxic and more effective than current treatments, which have a low survival rate. By understanding how these new analogues interact with cancer cells at a molecular level, the research seeks to improve treatment options for patients with Ewing sarcoma. The approach includes detailed biochemical and pharmacological studies to ensure the new drugs are both safe and effective.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with Ewing sarcoma.
Not a fit: Patients with other types of cancer or those who are not within the age range of 0-21 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for Ewing sarcoma, significantly improving survival rates for affected patients.
How similar studies have performed: Previous research has shown promise in targeting transcription factors with novel compounds, indicating potential for success in this approach.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Tsodikov, Oleg V — University of Kentucky
- Study coordinator: Tsodikov, Oleg V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.